Boehringer Ingelheim said that its investigational glucagon/GLP-1 dual agonist survodutide (BI 456906) being co-developed with Zealand Pharma met the co-primary endpoints of a Phase III study in adults living with #obesity or #overweight, leading to average #weightloss of 16.6%
All Calibrate members will be considered, as clinically appropriate, for Wegovy
$55 Skinny B12 + Glutathione Skinny B12 + Glutathione Glow 200mg for metabolism support and antioxidant skin benefits
All patients ( n = 209) with MM ( n = 41), NSCLC ( n = 91), urothelial cell carcinoma ( n = 8), renal cell carcinoma ( n = 21), head and neck cancer ( n = 28), gastric cancer ( n = 19) or Hodgkin lymphoma ( n = 1) treated with pembrolizumab or nivolumab between November 2, 2015 and October 31, 2018 at Nagoya University Hospital were included in this study, and observed until death or referral to another hospital
Use a simple scale from 0 to 5, a note app, or a quick voice memo
Weight-loss medications have moved from fringe conversations to mainstream healthcare discussions in a remarkably short space of time
